Item 1.01 Entry into a Material Definitive Agreement.
On February 19, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) completed its previously announced issuance of $600,000,000 aggregate principal amount of its 4.700% notes due 2027 (the “2027 Notes”), $550,000,000 aggregate principal amount of its 5.050% notes due 2030 (the “2030 Notes”) and $600,000,000 aggregate principal amount of its 5.500% notes due 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2030 Notes, the “Notes”).
The Notes were issued pursuant to the Twelfth Supplemental Indenture dated as of February 19, 2025 (the “Supplemental Indenture”), to the Company’s Indenture (the “Base Indenture”) dated as of November 17, 2009, between the Company and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as trustee. For a description of the material terms of the Supplemental Indenture and the Notes, see the information set forth below under Item 2.03, which is incorporated into this Item 1.01.
The offering of the Notes was made pursuant to the Registration Statement on Form S-3 (Registration No. 333-263051), the prospectus dated February 25, 2022, and the related prospectus supplement dated February 11, 2025.
Copies of the Base Indenture and the Supplemental Indenture are attached hereto as Exhibits 4.1 and 4.2, respectively, and are incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth above under Item 1.01 is incorporated into this Item 2.03.
Interest on the 2027 Notes accrues at a rate of 4.700% per annum, on the 2030 Notes at a rate of 5.050% per annum and on the 2035 Notes at a rate of 5.500% per annum, which interest, in each case, will be payable semi-annually in arrears on February 19 and August 19 of each year, commencing on August 19, 2025. Interest will be paid to the holders of record of the Notes at the close of business on the February 4 and August 4, respectively, immediately preceding the related interest payment date. The 2027 Notes will mature on February 19, 2027, the 2030 Notes will mature on February 19, 2030 and the 2035 Notes will mature on February 19, 2035.
The Company may redeem each series of the Notes at its option, in whole or in part, at any time and from time to time, prior to February 19, 2027 (the maturity date) in the case of the 2027 Notes, January 19, 2030 in the case of the 2030 Notes and November 19, 2034 in the case of the 2035 Notes (each, a “Par Call Date”), at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
|
(1) |
(a) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed, discounted to the redemption date (assuming the Notes matured on the applicable Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the Supplemental Indenture), plus 10 basis points, in the case of the 2027 Notes, or 15 basis points, in the case of each of the 2030 Notes and the 2035 Notes, less (b) interest accrued to the date of redemption; and |
|
(2) |
100% of the principal amount of the Notes to be redeemed; |
plus, in either case, accrued and unpaid interest thereon to the redemption date.
On or after the applicable Par Call Date, the Company may also redeem each of the 2030 Notes and the 2035 Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the Notes of such series being redeemed plus accrued and unpaid interest thereon to the redemption date.
As previously disclosed, the Company, certain of its subsidiaries and Paragon 28, Inc. (“Paragon 28”) have entered into an agreement and plan of merger (the “Paragon 28 Merger Agreement”), pursuant to which the Company will